All In Biotech

Drug Trial Radar · NCT00762190

Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

A Multicenter, Double-Blind, Placebo-Controlled, Randomized Study of the Safety of TAK-559 in the Treatment of Patients With Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Nov 12, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 348 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

348

Actual

Start

Nov 2003

Primary completion

Dec 2004

Study completion Dec 2004

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Sep 30, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 25 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine the safety of TAK-559, once daily (QD), in treating subjects receiving a stable dose of insulin to control type 2 diabetes mellitus.

Conditions

  • Diabetes Mellitus

Interventions

  • TAK-559 and insulinDrug

    TAK-559 32 mg, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.

  • InsulinDrug

    TAK-559 placebo-matching, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse events.Time frame: All visits or at occurrence.
  2. Clinical safety lab tests.Time frame: Weeks 12, 24, and Final Visit.
  3. 12-lead electrocardiogram.Time frame: Weeks: 24 and Final Visit.
  4. Urinalysis.Time frame: Weeks: 12, 24, 36, 48 and Final Visit.
  5. Change from Baseline in Blood pressure and pulse.Time frame: At all visits.
  6. Change from Baseline in Body weight.Time frame: At all visits.
  7. Left ventricular mass index by body surface area measured by echocardiogram.Time frame: Weeks: 24 and Final Visit.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.